CBS 2019
CBSMD教育中心
中 文

Scientific Library

Abstract

Recommended Article

Aggressive lipid-lowering therapy after percutaneous coronary intervention – for whom and how? Fine particulate air pollution and hospital admissions and readmissions for acute myocardial infarction in 26 Chinese cities Patterns of use of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers among patients with acute myocardial infarction in China from 2001 to 2011: China PEACE-Retrospective AMI Study Comparison of the Preventive Efficacy of Rosuvastatin Versus Atorvastatin in Post-Contrast Acute Kidney Injury in Patients With ST-segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention: A Consensus Document From the Academic Research Consortium for High Bleeding Risk Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes Effect of a Restrictive vs Liberal Blood Transfusion Strategy on Major Cardiovascular Events Among Patients With Acute Myocardial Infarction and Anemia: The REALITY Randomized Clinical Trial No causal effects of plasma homocysteine levels on the risk of coronary heart disease or acute myocardial infarction: A Mendelian randomization study

Original Research2018;7:e009806

JOURNAL:JAHA Article Link

Guideline‐Directed Medical Therapy for Patients With Heart Failure With Midrange Ejection Fraction: A Patient‐Pooled Analysis From the KorHF and KorAHF Registries

Ki Hong Choi Jin‐Oh Choi et al. Keywords: heart failure with midrange ejection fraction; HFmrEF; acute HF; β‐blocker; renin‐angiotensin system blocker; all‐cause mortality

FULL TEXT PDF